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Abstract
HIV-1 infection is initiated by the interaction of the envelope glycoprotein gp120 with the cellular receptor CD4 that triggers
conformational changes in gp120 necessary for subsequent interaction with a coreceptor CCR5 (or CXCR4). The CD4-induced (CD4i)
conformation of gp120 can be mimicked by a full-length single chain (FLSC) protein consisting of gp120 linked with the D1D2 domains of
CD4 by a 20-amino-acid linker. We have used this protein to establish a flow cytometry-based assay and an ELISA-based assay to identify
inhibitors that block the binding of gp120 to CCR5. Both assays are specific for detecting the known CCR5 antagonist TAK-779, but the
ELISA-based assay was more sensitive, simple, inexpensive, and rapid; thus, it can be adapted to high throughput screening (HTS). The
ELISA-based method was validated with a diverse set of known antagonists, for example, TAK-779, AOP-RANTES, PSC-RANTES, and
several mAbs.
D 2004 Elsevier Inc. All rights reserved.
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The discovery of T-20 (Fuzeon; enfuvirtide) (Wild et al.,
1994) and its recent approval by the United States Food and
Drug Administration (FDA) (Cervia and Smith, 2003; Kilby
et al., 1998) as a new class of anti-HIV-1 agents, termed
entry inhibitors, resulted in renewed hope that the initial
steps of HIV-1 infection, that is, fusion and entry, can be
effectively blocked. Furthermore, this drug is effective in
HIV-1-infected people who are resistant to other existing
anti-HIV-1 drugs. Therefore, identification of compounds
that inhibit the early steps of HIV-1 infection has drawn
considerable attention lately. HIV-1 infection is mediated by0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: adebnath@nybloodcenter.org (A.K. Debnath).attachment of the virus surface envelope glycoprotein gp120
to the CD4 receptor and subsequently to chemokine
receptors, CXCR4 or CCR5 (Brelot and Alizon, 2001;
Moore et al., 1997; Sodroski, 1999; Stein and Engleman,
1991). CCR5 belongs to the family of G-protein coupled
receptors (GPCR) and was discovered as the major chemo-
kine receptor for the macrophage tropic strains (M-tropic) of
HIV-1 based on the observation that the h-chemokines,
MIP-1a, MIP-1h, and RANTES inhibit infection of CD4+
cells by nonsyncytium-inducing (NSI) strains of HIV-1
(Cocchi et al., 1995). CCR5 is also the primary coreceptor
for HIV-1 infection through sexual transmission (D’Ubaldo
et al., 1999; O’Brien et al., 1998). The findings that some
individuals homozygous for a defective CCR5 allele with an
internal 32 base pair deletion (CCR5-D32) were resistant to
infection with R5 viruses and appeared to be healthy (Liu et
al., 1996; Marmor et al., 2001; Samson et al., 1996)
reinforced the notion that CCR5 could be a possible target
for early therapeutic intervention against HIV-1 infection.04) 299–309
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can be effectively inhibited by addition of CCR5-specific
ligands as well as CCR5-neutralizing antibodies to cells
(Cocchi et al., 1995; Simmons et al., 1997). A plethora of
publications, especially from pharmaceutical companies,
have emerged recently reporting the discovery of new
classes of small molecule CCR5 antagonists (Baba et al.,
1999; Hale et al., 2001a; Kazmierski et al., 2003; Lynch
et al., 2002; Maeda et al., 2001; Strizki et al., 2001).
Some of the reported data has recently been used to map
possible pharmacophore sites of CCR5 antagonists (Deb-
nath, 2003; Finke et al., 2001). The results from early
clinical trials also indicated that CCR5 coreceptor can be
used as a viable target for antiretroviral therapy (Pozniak
et al., 2003; Reynes et al., 2002).
Several methods to identify CCR5 antagonists have
been reported (Chiba et al., 2001; Holland et al., 2004;
Jenkinson et al., 2003a, 2003b; Nussbaum et al., 1994;
Spenlehauer et al., 2001). The conventional CCR5
antagonist binding assay uses inhibition of chemokine
binding and requires a radio-labeled chemokine, such as
[I125]RANTES or [I125]MIP-1a or [I125]MIP-1h as a
competition agent (Baba et al., 1999; Hale et al., 2001b;
Strizki et al., 2001). Recently, Jenkinson et al. (2003b),
who developed a baculovirus based assay, pointed out that
the labeled chemokine-based approach has several limi-
tations: (1) missing inhibitors that do not bind directly to
the chemokine binding site in CCR5 but may bind to other
sites of the coreceptor responsible for gp120-CCR5 bind-
ing. It has been reported that at least one of the sites for
gp120 binding on CCR5 is distinct from the chemokineFig. 1. Schematics of gp120–CD4 and FLSC binding to CCR5. (A) The envelope
dots) on gp120, which subsequently bind to the CCR5 chemokine receptor [repr
gp120 (green) and D1D2 domains of CD4 (blue), which already has exposed CC
This binding process can be inhibited by CCR5 antagonists.binding site (Dragic et al., 1998); (2) failure to identify
inhibitors that target the CCR5 binding site on gp120; (3)
inhibitors of the gp120-CCR5 interaction due to allosteric
interference may be missed; and (4) the radio-labeled
ligands, in large scale use, may pose health risk to the
laboratory personnel, especially to pregnant woman.
Therefore, it is prudent to develop a simple assay system
that can overcome all the above problems.
The interaction between gp120 and CD4 induces
conformational changes in the envelope glycoprotein
gp120 resulting in exposure of epitopes necessary for the
subsequent binding of gp120 to the chemokine receptor
CCR5 (Wu et al., 1996). These epitopes are recognized by
two human monoclonal antibodies (mAbs), 17b and 48d
(Thali et al., 1993). Characterization of the 17b binding site
was provided from an X-ray crystal structure of the gp120
core complexed with a two-domain fragment of human CD4
and the Fab fragment of 17b (Kwong et al., 1998, 2000;
Rizzuto et al., 1998; Wyatt et al., 1998). Binding of these
mAbs blocked the interaction of gp120–CD4 complexes
with CCR5 (Cocchi et al., 1995), suggesting that gp120
attachment to CD4 creates or exposes a high-affinity
binding site for CCR5 that is involved in membrane fusion
and virus entry.
The potential utility of the gp120–CD4 complex in
subunit vaccine design has been reported by several groups
(Devico et al., 1996; Fouts et al., 2000; He et al., 2003).
Recently, a full-length single chain (FLSC) analogue of the
gp120–CD4 complex, consisting of HIV-1 BaL gp120
joined to the D1D2 domains of CD4 by a 20-amino-acid
linker, has been described (Fouts et al., 2000). This proteinglycoprotein gp120 binds to the CD4 receptor and induces epitopes (yellow
inted with permission (Farber and Berger, 2002)] (B) FLSC, consisting of
R5 binding epitopes (yellow dots), can bind directly to the CCR5 receptor.
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the gp120–CD4 complex, including increased exposure of
epitopes of the coreceptor-binding site on gp120, and
abolition of epitopes corresponding to the CD4 binding
site on gp120 that are occluded by complex formation.
Furthermore, FLSC bound specifically to the CCR5
coreceptor and blocked R5 virus infection (Fouts et al.,
2000), suggesting that these single-chain chimeric mole-
cules accurately mimicked the gp120–CD4 complex inter-
mediate that arises during HIV-1 binding to CD4+ cells
(Farber and Berger, 2002) (Fig. 1A). This further suggested
the potential utility of this single-chain protein as a mimic
for the gp120–CD4 complex (Dragic et al., 1998; Fouts et
al., 2000). We hypothesize that an inhibitor that blocks
FLSC from binding to the CCR5 chemokine receptor will
function as an efficient CCR5 antagonist (Fig. 1B).
We have utilized FLSC to develop (a) a flow cytometry-
based assay and (b) an ELISA-based assay. We report here
the systematic development of these assays and its useful-
ness in identifying inhibitors that prevent the binding of
gp120 to CCR5.Fig. 2. Demonstration of mAb 17b binding to FLSC and its inhibitory effect
on binding between FLSC- and CCR5-expressing cells. (A) mAb 17b was
added to wells of 96-well polystyrene plates that were precoated with either
BaL gp120, complex (equal molar concentrations of gp120-BaL and
sCD4), or FLSC (2 Ag/ml). The experiment was performed at 0.5, 1.0 and
2.0 Ag/ml concentrations and 2 Ag/ml was selected based on the optimum
absorbance values for both the FLSC protein and the complex compared to
gp120 at graded concentrations of 17b. The binding of mAb 17b was
detected by sequentially adding biotin-labeled goat-anti-human IgG,
streptavidin-labeled horseradish peroxidase (SA-HRP), and the substrate,
3,3V,5,5V-tetramethylbenzidine (TMB). Absorbance at 450 nm was deter-
mined spectrophotometrically by an ELISA reader. (B) Cf2Th/synCCR5
cells (1  106) were incubated with FLSC at the final concentration of 2 Ag/
ml in the presence or absence of mAb 17b at graded concentrations for 15
min at room temperature (RT). After thorough washing, the detecting
antibody, PE-conjugated M-T441, and the corresponding control Ab, PE-
conjugated mouse IgG2b isotype, were added. After 15 min of incubation at
RT and three times washing with HBSS, the cells were analyzed in a Becton
Dickinson FACSCalibur flow cytometer using CellQuest software. Percent
inhibition of binding of FLSC and complex with CCR5 by mAb 17b were
calculated from the mean fluorescence intensity (MFI) and plotted against
different doses of mAb 17b.Results
Development of flow cytometry-based assay to identify
CCR5 antagonists
We have confirmed the functional integrity of FLSC by a
series of experiments. We first verified whether FLSC
mimics the complex (made by mixing equal molar ratios of
sCD4-183 and the BaL gp120 and designated as bcomplexQ
throughout the article) by measuring its binding to the mAb
17b, which recognizes the CD4-induced binding site on
gp120. BaL gp120 alone was used as a control. mAb 17b
bound to both FLSC and complex with almost identical
affinity whereas BaL gp120 did not bind (Fig. 2A).We then
verified whether mAb 17b could inhibit the binding of
FLSC to CCR5 using flow cytometry. Because FLSC was
used as the mimic for the gp120–CD4 complex, we chose
Cf2Th/synCCR5 cells for this purpose. These cells do not
have CD4 receptors on their surface but express high level
of CCR5 (Mirzabekov et al., 1999). Initially, D7324, a
polyclonal sheep antibody, which recognizes the C terminal
15 amino acids of gp120, was used as antibody to detect
FLSC. Although the results were reasonable, a vast
improvement in sensitivity was achieved (data not shown)
when we used instead a mouse antibody M-T441 that
recognizes the D2 domain of CD4. Therefore, we have
used phycoerythrin (PE)-conjugated anti-CD4 mAb M-
T441 as detecting antibody and PE-conjugated mouse
IgG2b isotype as control. Fig. 2(B) shows that mAb 17b
inhibited the binding of FLSC and the complex to the
CCR5 expressed cells in an almost identical dose-depend-
ent fashion. These experiments confirmed that CD4-
induced binding sites are similar in the FLSC chimericprotein and the complex, and proved that this protein could
be used to design assays to identify inhibitors that prevent
the interaction between gp120 and CCR5.
The same assay method used for 17b inhibition was used
for identifying CCR5 antagonists. TAK-779 was used as a
CCR5 antagonist (Baba et al., 1999; Este, 2001) and AMD-
3100 as a CXCR4 antagonist (Bridger et al., 1999; Donzella
et al., 1998) to validate the assay. Fig. 3A shows the results of
flow cytometry analysis indicating that TAK-779 inhibited
the interaction between both FLSC (c–e) and complex (h–j)
Fig. 3. Flow cytometry analyses of TAK-779 and AMD-3100 inhibition of binding of FLSC and complex to Cf2Th/synCCR5 cells. (A, a) Negative control
(cells + FLSC + PE-conjugated mouse IgG2b isotype); (b) positive control (cells + FLSC + PE-conjugated M-T441); (c–e) in the presence of TAK-779 at 1000,
250, and 62.5 nM doses, respectively; (f and g) negative and positive controls, respectively, as in a and b, except that complex was used instead of FLSC; (h–j)
TAK-779 inhibition of the binding of the complex to CCR5 at the same dose range as in c–e; (k–o) AMD-3100 inhibition using identical conditions as in a–e
(the positive controls in b and l are from two different passage cells). (B) Dose–response plot of percent inhibition of TAK-779 calculated from MFI.
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 Fig. 4. Selection of detecting antibody for the cell-based ELISA. Cf2Th/
synCCR5 cells were fixed with 5% formaldehyde on a 96-well plate. The
FLSC, the gp120, and the complex were added to the cells at varied
concentrations (results using 1 Ag/ml were shown here). The binding of
FLSC was detected by sequentially adding (a) D7324, biotin-labeled goat-
anti-sheep IgG, SA-HRP, and TMB, or (b) M-T441, biotin-labeled anti-
mouse IgG, SA-HRP, and TMB. Absorbance at 450 nm was recorded in an
ELISA reader. Experiments were done in triplicate.
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On the contrary, AMD-3100 did not inhibit the binding
between FLSC and CCR5 (m–o). The MFI was used
to calculate the percent inhibition. TAK-779 inhibited the
interaction (Fig. 3B) with an EC50 of approximately 175 nM
for both.Table 1
EC50 values of a diverse set of CCR5 antagonists and controls
Target Antagonists
CCR5 small molecule TAK77
chemokine and chemokine analogs RANT
AOP-R
PSC-R
anti-CCR5 antibodies 2D7
3A9
CD4i anti-CD4i antibodies 17b
48d
F425 A
V3 loop small molecule MTCP
anti-V3 loop antibodies F425 B
F425 B
CXCR4 small molecule/peptide AMD-
T22
anti-CXCR4 antibody 12G5
CD4 anti-CD4 binding site antibody b12
Gp120 small molecule chloro
Gp41 peptides T20
C34
IgG controls mouse IgG2a mouse
human IgG human
a All the compounds have b15% inhibition up to 1000 nM.
b The antibodies and IgGs have b20% inhibition up to 15 Ag/ml.Development of an ELISA-based assay for CCR5
antagonists
Although the flow cytometry-based assay is specific in
identifying the CCR5 antagonist, TAK-779, the method
requires large quantities of both FLSC and detecting
antibodies. Therefore, it is not economical for high
throughput screening (HTS). Based on our previous
experience in developing an ELISA-based assay for
identifying CXCR4 inhibitors (Zhao et al., 2003), we
wanted to develop an ELISA-based assay in a micro-well
plate format so that only low quantities of FLSC and
antibodies would be required for the assay. Such method
could be routinely run in the laboratory and would be
amenable for high throughput screening. Furthermore, an
ELISA-based assay does not require any sophisticated
instrument as is the FACSCalliber.
The flow cytometry-based assay described above con-
firmed that the interaction between FLSC and CCR5 can
be detected using the anti-CD4 antibody M-T441 with
higher sensitivity than with the antibody D7324. We
wanted to confirm this finding in the ELISA-based assay
before selecting M-T441 as the detecting antibody to
determine the binding between FLSC and Cf2Th/synCCR5
cells. Fig. 4 shows that the mAb M-T441 was much more
sensitive in detecting FLSC than was D7324. Therefore,
we used M-T441 as the detecting antibody in all the
subsequent experiments.
We have shown earlier that FLSC mimics the BaL
gp120–CD4 complex in exposing the CD4i epitopes
recognized by the antibody 17b. Fig. 4 shows that theEC50
nM Ag/ml ng/ml
9 5.12
ES 172.38
ANTES 12.22
ANTES 42.04
0.75
7.47
9.78
25.77
1g8 30.59
P 3454.82
4a1 11.95
4e8 18.71
3100 no inhibitiona
no inhibitiona
no inhibitionb
no inhibitionb
peptin no inhibitiona
no inhibitiona
no inhibitiona
IgG2a no inhibitionb
IgG no inhibitionb
Fig. 5. The dose–response plot of TAK-779 inhibition of FLSC binding to
CCR5. Cf2Th/synCCR5 cells were plated, cultured, and fixed with 5%
formaldehyde on 96-well plates. FLSC was added to the cells in the
presence or absence of the indicated compounds in varied concentrations.
The binding of FLSC was detected by sequentially adding M-T441, biotin-
labeled anti-mouse IgG, SA-HRP, and TMB. Absorbance at 450 nm was
recorded in an ELISA reader. Each sample was tested in triplicate.
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fashion, when M-T441 was used for determination of FLSC
binding, whereas BaL gp120 did not bind to CCR5. This
result again confirmed that FLSC truly mimicked the
complex.
The purpose of the development of this ELISA-based
assay is to use it for identifying HIV-1 entry inhibitors,
targeted to CCR5. To determine the optimum concentrations
of both FLSC and M-T441 needed for obtaining the best
possible results with minimum effect on the sensitivity, we
measured the binding of FLSC to the Cf2Th/synCCR5 cells
using graded concentrations of FLSC and M-T441 (15.6–
2000 ng/ml). The optimum concentrations determined for
FLSC and M-T441 were 125 and 250 ng/ml, respectively,
and were selected for the ELISA-based assay.
To investigate the optimum fixation time of the Cf2Th/
synCCR5 cells on 96-well plates, cells were fixed with 5%
formaldehyde in 0.01 M phosphate-buffered saline (PBS)
for 5, 20, and 30 min at room temperature. The longer
fixation time did not improve the detection of the known
CCR5 inhibitor (TAK-779) tested for this purpose. There-
fore, in all subsequent assays, a fixation time of 5 min was
used.
Potential utility of the ELISA-based assay for identifying
CCR5 antagonists
In order to assess the validity and usefulness of this
simple cell-based ELISA to identify CCR5 antagonists, we
have selected several categories of possible CCR5 antago-
nists and tested their inhibitory activity in this assay. We
selected TAK-779 (Baba et al., 1999) as the only small
molecule CCR5 antagonist available from the AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH. We also selected RANTES and its two
analogs AOP-RANTES (Proudfoot et al., 1999; Simmons
et al., 1997; Torre et al., 2000) and PSC-RANTES (Pastore
et al., 2003), which were shown to effectively block gp120
binding to CCR5. Several monoclonal antibodies were also
selected to test their potential inhibitory activity, for
example, mAbs 2D7 and 3A9 were selected as anti-CCR5
antibodies (Wu et al., 1996, 1997a, 1997b). We have also
selected three anti-CD4i mAbs, 17b (Kwong et al., 1998;
Sullivan et al., 1998; Wyatt et al., 1998), 48d (Moore et al.,
1993; Thali et al., 1993), and F425 A1g8 (Cavacini et al.,
2003), and two anti-V3 loop mAbs, F425 B4a1 and F425
B4e8 (Cavacini et al., 2003). Several non-CCR5 targeted
mAbs, mouse, and human IgG and small molecule entry
inhibitors were chosen as negative controls. We chose b12,
an anti-CD4 binding site mAb (Burton et al., 1991, 1994),
and 12G5, an anti-CXCR4 mAb (Endres et al., 1996),
AMD-3100 (Bridger et al., 1999; Donzella et al., 1998) and
T22 (Murakami et al., 1999; Nakashima et al., 1992), two
known CXCR4 antagonist as negative controls. A variety of
other entry inhibitors reported were also selected, for
example, chloropetin (Matsuzaki et al., 1994) was selectedas an envelope glycoprotein gp120 inhibitor, meso-tetra (4-
carboxyphenyl)-porphyrin (MTCPP) (Debnath et al., 1994;
Neurath et al., 1995), a gp120 inhibitor targeted to the V3
loop, C34 (Chan et al., 1997; Lu and Kim, 1997) and T20
(Cervia and Smith, 2003; Wild et al., 1994), two known
inhibitors targeted to the HIV-1 envelope glycoprotein gp41.
Because some of the mAbs were mouse and human origin,
respectively, we have also tested mouse IgG and human IgG
as controls. Table 1 shows the corresponding results
obtained in the cell-based ELISA assay. Except for the
reagents used as negative controls, all other antagonists
showed dose-dependent inhibition, and their corresponding
EC50 values are shown in Table 1. The dose–response curve
for TAK-779 is shown as an example (Fig. 5).Discussion
The discovery of CCR5 and CXCR4 chemokine recep-
tors and subsequent understanding of their importance in
HIV-1 tropism and virus entry opened up an important field
for AIDS research (Berger et al., 1999; Moore et al., 1997).
CCR5 has emerged as the principal coreceptor because
CCR5-using viruses are found exclusively during the early
and the clinical latent phase of HIV-1 infection as well as
during the late-stage of the disease in more than half of the
infected people (Cilliers et al., 2003). Earlier studies showed
that subtype C isolates almost exclusively use CCR5 as the
coreceptor. HIV-1 subtype C now accounts for more than
half of the new infections worldwide, especially in devel-
oping countries, such as South Africa, India, and China
(Cilliers et al., 2003). These facts and the observation that
some individuals who were homozygous for a defective
CCR5 allele with an internal 32 base pair deletion (CCR5-
D32) in the CCR5 gene were protected from HIV-1
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et al., 1996; Marmor et al., 2001; Samson et al., 1996)
justify the use of CCR5 as target for developing a new class
of anti-HIV-1 agents.
The clinical success of the peptide-based inhibitor T-20,
which targets the HIV-1 envelope glycoprotein gp41 and its
recent approval by the US FDA as the only entry inhibitors,
so far, generated renewed hope for identifying inhibitors that
target early steps of the HIV-1 life cycle, such as CCR5
antagonists. Identification of small molecule drugs against
this target has been recently reviewed (Kazmierski et al.,
2003). The first discovery of a CCR5 antagonist, TAK-
779, was reported by Takeda Chemical Industries in Japan
(Baba et al., 1999). Recently, several reports emerged on
the systematic discovery of highly potent CCR5 antagonists
as anti-HIV-1 agents (Castonguay et al., 2003; McCombie
et al., 2003; Palani et al., 2001, 2002; Strizki et al., 2001;
Tagat et al., 2001; Trkola et al., 2002; Tsamis et al., 2003;
Willoughby et al., 2003). Results on phase I/II studies
(Reynes et al., 2002) of one of the CCR5 antagonists, SCH-
C, from Schering-Plough Research Institute were presented
at the 9th Conference on Retroviruses and Opportunistic
Infections (February 24–28, 2002, Seattle). In another
report, presented at the 43rd Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC) (Sep-
tember 13–17, 2003, Chicago), an investigational CCR5
antagonist from Pfizer, UK-427857, showed encouraging
results in phase I clinical trials (Pozniak et al., 2003).
High throughput screening (HTS) assays using radio-
labeled 125I-RANTES or 125I-MIP-1a, natural ligands of
CCR5 receptors, have been traditionally used to identify
CCR5 antagonists. Although these methods were successful
in identifying highly active CCR5 antagonists, they have
limited utility in high throughput settings due to the reasons
described in the introduction.
Although many studies focused on the interaction of
CCR5 with HIV-1, the specific interaction sites in CCR5
and gp120 are yet not fully defined. Therefore, it was
prudent to develop an assay that reflects the process of
gp120 interaction with CCR5 during HIV-1 infection
without targeting any specific sites on CCR5 or gp120.
Toward this goal, we have utilized the Cf2Th/synCCR5 cell
line and FLSC to set up a simple model to study the
interaction between gp120 and CCR5. Because Cf2Th/
synCCR5 cells do not express CD4, gp120 does not bind to
these cells. This was demonstrated by both FACS analysis
and cell-based ELISA. Furthermore, FLSC mimics the
complex formed by gp120 and sCD4-183 as demonstrated
by its binding to the antibody 17b and the inhibition of the
binding of FLSC to CCR5. In our initial attempt to develop
the assays, we used a flow cytometry-based readout
technique. This method was able to successfully identify
TAK-779 as an antagonist at a low nanomolar dose level,
whereas AMD-3100, a CXCR4 antagonist, had no inhib-
itory activity at a 100 AM level (data not shown). This
method, although simple, is not convenient for large scaleuse, especially in high throughput settings. Therefore, we
developed an ELISA-based method using FLSC and the cell
line Cf2Th/synCCR5. Because the cells were fixed in the
cell-based assay, a mild fixing reagent (5% formaldehyde)
and a short fixing time were used to preserve the conforma-
tional integrity of CCR5. After systematic optimization of
the experimental conditions, the ELISA-based method was
used to measure the inhibitory activity of several antagonists
(Table 1). They can exert their effect on gp120 binding to
CCR5 directly or through allosteric modulation (Rees et al.,
2002) or bind to the CD4i epitopes or to the V3 loop of gp120
and thereby prevent the binding of gp120–CD4 complexes
(FLSC or complex) to CCR5. We have used TAK-779 as the
only available small molecule CCR5 antagonist that directly
binds to CCR5. The chemokine analogs AOP-RANTES and
PSC-RANTES, two very potent CCR5 antagonists, were
shown to exert their inhibitory activity through induction of
CCR5 receptor internalization and prevention of recycling of
CCR5 to the cell surface (Mack et al., 1998). The binding of
FLSC to CCR5-expressing cells could be effectively blocked
at low nanomolar doses by the CCR5 antagonist TAK-779
(EC50 = 5.12 nM) and by RANTES analogs in a dose-
dependent manner. RANTES by itself, though active,
showed less activity compared with TAK-779 and the
RANTES analogs. The apparent lower sensitivity of the
flow cytometry-based method in detecting TAK-779 (EC50 =
175 nM) compared to the above result in the cell-based
ELISA could probably be attributed to the fact that in the
flow cytometry-based assay, FLSC concentrations needed
for detection were much higher (2 Ag/ml) compared with
FLSC concentration in the cell-based ELISA (0.125 Ag/ml).
Therefore, a higher concentration of TAK-779 was required
to compete with FLSC.
Two anti-CCR5 mAbs, 2D7 and 3A9, respectively,
inhibited the binding. The inhibitory potency of 2D7 was
much better than that of 3A9, in agreement with published
reports (Wu et al., 1997a, 1997b). Because the method
measures the inhibition of FLSC binding to CCR5, we also
selected three mAbs that recognize CD4i epitopes and two
mAbs targeted to the V3 loop of gp120. All these mAbs
showed potent inhibition. We tested meso-tetra(4-carbox-
yphenyl) porphyrin (MTCPP), shown to bind to the V3 loop
of gp120 (Debnath et al., 1994; Neurath et al., 1995).
MTCPP also had inhibitory activity (Table 1). Because the
CCR5 binding site on gp120 also involves the V3 loop
(Cormier and Dragic, 2002), it is expected that this method
will be able to detect such inhibitors. We have used two
small molecule inhibitors AMD-3100 and T-22, which are
known to target CXCR4, as controls. Two mAbs, such as
b12, an anti-CD4 binding site antibody, and 12G5, an anti-
CXCR4 antibody, and both normal mouse IgG2a and
human IgG, were also used as controls. None of these
reagents showed any appreciable activity up to the dose
levels tested (Table 1). The data presented in this study
validate the cell-based ELISA assay and confirm that the
assay is simple and capable of detecting inhibitors targeted
Q. Zhao et al. / Virology 326 (2004) 299–309306to a variety of sites on CCR5 or gp120 and the CD4i
epitopes, which prevent the binding of FLSC to the CCR5.
Although CD4 and gp120 could have been used to
perform the same assay, their cost for routine use is
prohibitive. Dragic et al. (2000) used a similar method as
described above but they have used a complex of gp120 and
CD4-IgG2 to determine the inhibitory effect of TAK-779.
The method was sensitive but CD4-IgG2 is a proprietary
complex from Progenics (Terrytown, NY) and off limit to
most researchers. Therefore, this newly developed cell-
based assay is simple, rapid, economical, and sensitive, and
the method has the potential to be adapted in high
throughput settings. This assay does not require the use of
any infectious agents; therefore, no special biosafety
measures are needed in the laboratory for the experiments.Materials and methods
Reagents
The plasmids expressing recombinant FLSC (pEF6-
FLSC) and Bal gp120 (pBaL gp120) were provided by Dr.
Abraham Pinter at the Public Health Research Institute with
the permission from Dr. Anthony L. DeVico (Fouts et al.,
2000). Stable cell lines expressing recombinant proteins were
established by transfecting plasmids into 293T cells using
FuGene 6 (Boehringer Mannheim, Indianapolis, IN) accord-
ing to the manufacture’s protocol. Soluble FLSC and BaL
gp120 were purified from cell culture medium by lectin
chromatography withGalanthus nivalis snowdrop agglutinin
(Sigma-Aldrich, St. Louis, MO) as described (Gilljam, 1993).
Peptides T22, T20, and C34 were synthesized by a
standard solid-phase FMOC method in the MicroChemistry
Laboratory of the New York Blood Center. Chloropeptin
was a generous gift from Dr. Satoshi Omura of Kitasato
University, Japan. MTCPP was purchased from Porphyrin
Products (Logan, UT). AOP-RANTES and PSC-RANTES
were generously provided by Drs. Robin Offord and Oliver
Hartley, Universite´ de Gene`ve, Switzerland.
The following reagents were obtained through the AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH: Cf2Th/synCCR5 cell line from Drs.
Tajib Mirzabekov and Joseph Sodroski; sCD4-183, the first
two domains of the soluble CD4, from Garlick RL et al.;
mAbs against gp120 CD4 binding site (IgG1 b12 from Drs.
Dennis Burton and Paul Parren), against CD4i sites (17b
and 48d from Dr. James E. Robinson, and F425 A1g8 from
Drs. Marshall Posner and Lisa Cavacini), against V3 loop
(F425 B4a1 and F425 B4e8 from Dr. Marshall Posner and
Dr. Lisa Cavacini), and against CCR5 (2D7 and 3A9 from
Millennium Pharmaceuticals, Inc. and PharMingen); TAK-
779 from Takeda Chemical Industries; and AMD-3100 from
AnorMED. M-T441, biotinyl-M-T441, and PE-conjugated
M-T441 which recognize the domain two region of CD4
and the isotype control (IgG2b) and PE-conjugated mouseIgG2b was purchased from Ancell (Bayport, MN). D7324, a
polyclonal sheep antibody raised against a peptide derived
from the C-terminal 15 amino acids of gp120, was
purchased from Cliniqa (Fallbrook, CA). Anti-sheep IgG
and anti-mouse IgG (both biotin-labeled) were from Zymed
(S. San Francisco, CA) and Chemicon (Temecula, CA),
respectively. RANTES was purchased from BioSource
International (Camarillo, CA). Recombinant soluble CD4
(sCD4) was obtained from Immunodiagnostics Inc.
(Woburn, MA). The complex was formed by mixing the
equal molar concentrations of sCD4-183 and the gp120
(BaL). mAb 12G5 against CXCR4, mouse IgG2a, and
human IgG were purchased from R&D systems (Minneap-
olis, MN) and Zymed, respectively.
Flow cytometry analysis
Cf2Th/synCCR5 cells (1  106) were incubated for 15
min at room temperature in Hanks’ balanced salt solution
(HBSS) (Sigma) with FLSC at the final concentration of 2
Ag/ml in the presence or absence of the compounds tested.
After thorough washing, the binding of FLSC to CCR5 was
detected by PE-conjugated M-T441. PE-conjugated IgG2b
isotype was used as control. Both these PE-conjugated Abs
at 5 Ag/ml were added and incubated at room temperature
for 15 min. After extensive washing, cells were resuspended
and analyzed in a Becton Dickinson FACSCalibur flow
cytometer (Mountain View, CA) using CellQuest software.
Dead cells were excluded by propidium iodide staining.
Live cells were gated on their forward and side light scatter
characteristics and the MFI was measured.
When D7324 was used as the detecting antibody, normal
sheep IgG was used as control. A concentration of 10 Ag/ml
each was used. The cells were analyzed using FITC-
conjugated anti-sheep IgG (1:200) as the second read-out
antibody following the method described above.
Cell-based ELISA
Cf2Th/synCCR5 cells in DMEM medium supplemented
with 10% FBS, 1% penicillin/streptomycin, 500 Ag/ml
G418, 500 Ag/ml zeocyn, and 3 Ag/ml puromycin were
seeded into 96-well plates and cultured into a monolayer of
90% confluency at 37 8C overnight. Cells were fixed with
5% formaldehyde in 0.01 M phosphate-buffered saline
(PBS) for 5 min at room temperature. The plates were
washed three times with PBS containing 0.05% Tween 20
(PBST) and blocked with 5% nonfat dry milk in 0.01 M
PBS (pH 7.2) at 4 8C overnight. The FLSC, the gp120, or
the complex was added at graded concentrations (0.0625–4
Ag/ml) and incubated at 37 8C for 1 h. Detecting Abs and
their corresponding control Abs were added, respectively, as
previously described in the Flow cytometry analysis section.
After incubation at 37 8C for 1 h, the unbound antibodies
were removed by washing plates three times with PBST.
Then 100 Al of biotin-labeled second Abs (anti-sheep IgG
Q. Zhao et al. / Virology 326 (2004) 299–309 307and anti-mouse IgG, respectively) were added, followed by
incubation at 37 8C for 1 h. After extensive washes, 100 Al
of streptavidin-labeled horseradish peroxidase (SA-HRP)
(0.125 Ag/ml) was added and incubated at 37 8C for 1 h.
Subsequently, the substrate 3,3V,5,5V-tetramethylbenzidine
(TMB) was added. After 5 min at room temperature,
reactions were terminated by addition of 1 N H2SO4.
Absorbance at 450 nm (A450) was recorded in an ELISA
reader (Dynatech Laboratories, Inc., Chantilly, VA). Each
sample was tested in triplicate.
For measuring the inhibitory activity of anti-HIV-1 agents
on the binding of FLSC to the CCR5-expressing cells, the test
compounds were added to the fixed Cf2Th/synCCR5 cells
before addition of the FLSC. Binding of FLSC to the CCR5-
expressing cells was measured as described above (in case of
mouse antibodies, e.g., 2D7, 3A9, etc., biotinyl-M-T441 was
used as detecting antibody), and the inhibitory activity of the
compounds on FLSC binding was calculated using the
following formula: [1  (E  N)/(P  N)]  100%. N
represents the absorbance at 450 nm in the negative control
(the control Ab), while P corresponds to that in positive
control (detecting Ab). E corresponds to the absorbance in
experimental group where the test compounds were added
before addition of FLSC. EC50 (the concentration for 50%
inhibition) values were calculated using the GraphPad Prism
software (GraphPad Software Inc., San Diego, CA).Acknowledgement
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